1-(3-溴-5-硝基苯基)乙酮 | 127413-59-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(3-溴-5-硝基苯基)乙酮
• 英文名称: 1-(3-bromo-5-nitrophenyl)ethanone
• 英文别名: 1-(3-bromo-5-nitrophenyl)ethan-1-one
• CAS: 127413-59-6
• 化学式: C₈H₆BrNO₃
• 分子量: 244.045
• InChiKey: KMNMBNPBERMCLJ-UHFFFAOYSA-N

物化性质

• 沸点：
  293.4±25.0 °C(Predicted)
• 密度：
  1.637±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  62.9
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2914700090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温下应保持干燥密封保存。

反应信息

• 作为反应物：
  描述：

  1-(3-溴-5-硝基苯基)乙酮 在 copper(l) iodide 、 氨基甲酸叔丁酯 、 potassium carbonate 、 N,N'-二甲基乙二胺 、 三氟乙酸 作用下， 以 甲苯 、 二氯甲烷 为溶剂， 生成 1-(3-氨基-5-硝基-苯基)乙酮
  参考文献：
  名称：

  Fragment-Based Drug Discovery of 2-Thiazolidinones as BRD4 Inhibitors: 2. Structure-Based Optimization

  摘要：

  The signal transduction of acetylated histone can be processed through a recognition module, bromodomain. Several inhibitors targeting BRD4, one of the bromodomain members, are in clinical trials as anticancer drugs. Hereby, we report our efforts on discovery and optimization of a new series of 2-thiazolidinones as BRD4 inhibitors along our previous study. In this work, guided by crystal structure analysis, we reversed the sulfonamide group and identified a new binding mode. A structure-activity relationship study on this new series led to several potent BRD4 inhibitors with IC50 of about 0.05-0.1 mu M in FP binding assay and GI50 of 0.1-0.3 mu M in cell based assays. To complete the lead-like assessment of this series, we further checked its effects on BRD4 downstream protein c-Myc, investigated its selectivity among five different bromodomain proteins, as well as the metabolic stability test, and reinforced the utility of 2-thiazolidinone scaffold as BET bromodomain inhibitors in novel anticancer drug development.

  DOI：

  10.1021/jm501504k
• 作为产物：
  描述：

  间硝基苯乙酮 在 1,3,5-三溴-1,3,5-噻嗪烷-2,4,6-三酮 作用下， 以 三氟乙酸 为溶剂， 反应 1.0h， 以70%的产率得到1-(3-溴-5-硝基苯基)乙酮
  参考文献：
  名称：

  三氟乙酸中的三溴异氰尿酸：一种用于中等失活芳烃平稳溴化的有效系统

  摘要：

  中度失活的芳烃通过与三溴异氰脲酸（0.34 摩尔当量）在室温下在三氟乙酸中反应而被有效溴化，分离产率为 48-85%。这种介质避免了底物的多溴化，在 98% H 2 SO 4 中进行的相同反应中观察到。

  DOI：

  10.1055/s-0032-1317795

文献信息

• [EN] BICYCLIC HETEROCYCLYL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLYLE BICYCLIQUES ET LEURS UTILISATIONS
  申请人：REVOLUTION MEDICINES INC

  公开号：WO2020180770A1

  公开（公告）日：2020-09-10

  The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.

  本公开涉及SOS1的调节剂及其在治疗疾病中的应用。还公开了包含相同成分的药物组合物。
• [EN] BRANCHED MOIETY FOR USE IN CONJUGATES<br/>[FR] FRACTION RAMIFIÉE DESTINÉE À ÊTRE UTILISÉE DANS DES CONJUGUÉS
  申请人：MEDIMMUNE LLC

  公开号：WO2021080608A1

  公开（公告）日：2021-04-29

  A tri-functional linker moiety: formula (I), where X and Y are linking chains, and its use for preparing dual-mechanistic drug conjugates, preferably in a site-specific manner.

  一种三功能连接物：式（I），其中X和Y是连接链，以及其用于以特定位点方式制备双机制药物结合物的用途。
• Oxazine Derivatives and their Use in the Treatment of Neurological Disorders
  申请人：BADIGER Sangamesh

  公开号：US20120172359A1

  公开（公告）日：2012-07-05

  The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.

  该发明涉及一种新颖的杂环化合物，其化学式为其中所有变量如规范中定义的，在自由形式或盐形式中，其制备方法，其医药用途以及包含它们的药物。
• OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
  申请人：BADIGER Sangamesh

  公开号：US20110021520A1

  公开（公告）日：2011-01-27

  The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.

  本发明涉及新型杂环化合物，其化学式为所述变量均按规范中定义的方式，以自由形式或盐形式存在，涉及它们的制备，医药用途以及包含它们的药物。
• Oxazine derivatives and their use in the treatment of neurological disorders
  申请人：Novartis AG

  公开号：US08338413B1

  公开（公告）日：2012-12-25

  The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.

  该发明涉及一种新颖的杂环化合物，其化学式为上述所有变量均如规范中定义的形式，可为自由形式或盐形式，涉及其制备，医药用途以及包括它们的药物。